Comparing Synaptogenix (NASDAQ:TAOX) & Petros Pharmaceuticals (NASDAQ:PTPI)

Synaptogenix (NASDAQ:TAOX) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Profitability

This table compares Synaptogenix and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Analyst Ratings

This is a summary of current ratings and target prices for Synaptogenix and Petros Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Petros Pharmaceuticals	0	0	0	0	0.00

Valuation and Earnings

This table compares Synaptogenix and Petros Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300,000.00	93.62	-$28.74 million	($13.28)	-0.28
Petros Pharmaceuticals	$5.11 million	0.02	-$8.16 million	($1.64)	-0.00

Petros Pharmaceuticals has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 12.2% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Synaptogenix has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.

Summary

Petros Pharmaceuticals beats Synaptogenix on 9 of the 11 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.